Bristol-Myers Squibb Company (BMY - Free Report) announced an exclusive clinical collaboration agreement with PsiOxus Therapeutics under which the safety, tolerability and preliminary efficacy of PsiOxus’ enadenotucirev will be evaluated in combination with Bristol-Myers’ immuno-oncology drug Opdivo for the treatment of a range of tumor types in late-stage cancer patients.
The clinical collaboration will include phase I studies to assess whether this combination can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
We note that Opdivo is a PD-1 immune checkpoint inhibitor while enadenotucirev is a systemically administered oncolytic adenovirus therapeutic.
The deal will see Bristol-Myers shelling out a one-time upfront payment of $10 million to PsiOxus. While both parties will share development costs, PsiOxus will be responsible for conducting a phase I study with patient enrollment expected to commence in the third quarter of 2016. In addition, the companies will work exclusively with each other on anti-PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens. Moreover, Bristol-Myers will be eligible to get a time-limited right of exclusive negotiation for the commercial rights to enadenotucirev.
We are positive on this deal. Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with other regimens. The drug recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Some other equally ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Pfizer Inc. (PFE - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Bristol-Myers Squibb Company (BMY - Free Report) announced an exclusive clinical collaboration agreement with PsiOxus Therapeutics under which the safety, tolerability and preliminary efficacy of PsiOxus’ enadenotucirev will be evaluated in combination with Bristol-Myers’ immuno-oncology drug Opdivo for the treatment of a range of tumor types in late-stage cancer patients.
The clinical collaboration will include phase I studies to assess whether this combination can significantly improve the proportion of patients achieving objective tumor responses, the extent of tumor shrinkage, and/or the durability of responses.
We note that Opdivo is a PD-1 immune checkpoint inhibitor while enadenotucirev is a systemically administered oncolytic adenovirus therapeutic.
The deal will see Bristol-Myers shelling out a one-time upfront payment of $10 million to PsiOxus. While both parties will share development costs, PsiOxus will be responsible for conducting a phase I study with patient enrollment expected to commence in the third quarter of 2016. In addition, the companies will work exclusively with each other on anti-PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens. Moreover, Bristol-Myers will be eligible to get a time-limited right of exclusive negotiation for the commercial rights to enadenotucirev.
We are positive on this deal. Bristol-Myers is collaborating with several other companies for the evaluation of Opdivo in combination with other regimens. The drug recorded worldwide revenues of $942 million in 2015. Label expansion into additional indications would give Opdivo access to an expanded patient population and increase the commercial potential of the drug.
Bristol-Myers is a Zacks Rank #1 (Strong Buy) stock. Some other equally ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Retrophin, Inc. and Pfizer Inc. (PFE - Free Report) .
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BMY - FREE
Get the latest research report on PFE - FREE
Get the latest research report on ANIP - FREE